Clinical Genomics’ gene-based blood test Colvera a first

01 June 2018

Home grown success story drives the commercialisation of Colvera™, a liquid biopsy test for colorectal cancer (CRC) recurrence, and the focus of growing clinical evidence to support its use as the first widely adopted blood test for screening for colorectal cancer.

Colvera - News

OneVentures played a key role in the financing by increasing their position in Clinical Genomics and enabling many of their limited partners to invest further.

OneVentures Managing Partner and Clinical Genomics Director Paul Kelly MD said, “The company is poised to achieve some very significant milestones over the next couple years that should further drive revenue and value growth.”

Learn More

You may also like

12 January 2021

Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®

News, Media Release

15 November 2020

Clinical Genomics Announces Medicare Coverage Applicable to COLVERA® (Liquid Biopsy Test to Detect Recurrence of Colorectal Cancer)

27 May 2020

Clinical Genomics announces publication of Additional positive data reinforcing key benefits of COLVERA®

30 April 2020

Clinical Genomics expands strategic relationship with Quest Diagnostics and further increases momentum for innovative first-line colorectal cancer screening blood test

View All

Ventured. Gained.

Subscribe to our Newsletter.

Name
This field is for validation purposes and should be left unchanged.
decor